Clinical Trial Detail

NCT ID NCT04322643
Title Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

transitional cell carcinoma

Therapies

Durvalumab

Pembrolizumab

Avelumab

Nivolumab

Atezolizumab

Age Groups: adult senior

No variant requirements are available.